Kimberley Goldsmith

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Kimberley A. Goldsmith is a researcher and senior lecturer at the Mental Health and Neuroscience Clinical Trials Unit, Institute of Psychiatry, King's College, London.[1]

Notable studies[edit | edit source]

PACE trial publications include:

Main trial outcome
Other PACE trial publications

Letters[edit | edit source]

PACE trial authors' responses
  • 2019, The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et al[14] (Full text)

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

  • PubMed
  • Twitter
  • Facebook
  • Website
  • YouTube

See also[edit | edit source]

Learn more[edit | edit source]

  • King's College, London

References[edit | edit source]

  1. ↑ "Kimberley Goldsmith - Research Portal, King's College, London". kclpure.kcl.ac.uk. Retrieved October 16, 2018.
  2. ↑ White, PD; Goldsmith, KA; Johnson, AL; Potts, L; Walwyn, R; DeCesare, JC; Baber, HL; Burgess, M; Clark, LV; Cox, DL; Bavinton, J; Angus, BJ; Murphy, G; Murphy, M; O'Dowd, H; Wilks, D; McCrone, P; Chalder, T; Sharpe, M; The PACE Trial Management Group (March 5, 2011). "Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial". The Lancet. 377 (9768): 823–836. doi:10.1016/S0140-6736(11)60096-2. PMID 21334061.
  3. ↑ McCrone, P; Sharpe, M; Chalder, T; Knapp, M; Johnson, AL; Goldsmith, K (August 1, 2012). "Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis". PLoS One. doi:10.1371/journal.pone.0040808. PMID 22870204.
  4. ↑ White, PD; Goldsmith, K; Johnson, AL; Chalder, T; Sharpe, M; PACE Trial Management Group (October 2013). "Recovery from chronic fatigue syndrome after treatments given in the PACE trial". Psychol Med. 43 (10): 2227-2235. doi:10.1017/S0033291713000020. PMID 3776285.
  5. ↑ Walwyn, R; Potts, L; McCrone, P; Johnson, AL; DeCesare, JC; Baber, HL; Goldsmith, KA; Sharpe, M; Chalder, T; White, PD (November 13, 2013). "A randomised trial of adaptive pacing therapy, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome (PACE): statistical analysis plan". Trials Journal. doi:10.1186/1745-6215-14-386.
  6. ↑ Dougall, D; Johnson, A; Goldsmith, K; Sharpe, M; Angus, B; Chalder, T; White, P (July 2014). "Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome". Journal of Psychosomatic Research. 77 (1): 20-26. doi:10.1016/j.jpsychores.2014.04.002.
  7. ↑ Chalder, T; Goldsmith, KA; White, PD; Sharpe, M; Pickles, AR (January 28, 2015). "Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial". The Lancet Psychiatry. 2 (2): 141–52. doi:10.1016/S2215-0366(14)00069-8. PMID 26359750.
  8. ↑ Sharpe, M; Goldsmith, KA; Johnson, AL; Chalder, T; Walker, J; White, PD (October 27, 2015). "Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial". The Lancet Psychiatry. 2: 1067–74. doi:10.1016/S2215-0366(15)00317-X. PMID 26521770. There was little evidence of differences in outcomes between the randomised treatment groups at long-term follow-up.
  9. ↑ Goldsmith, KA; Chalder, T; White, PD; Sharpe, M; Pickles, AR (November 17, 2015). "Longitudinal mediation in the PACE randomised clinical trial of rehabilitative treatments for chronic fatigue syndrome: modelling and design considerations". Trials Journal / Paperity.
  10. ↑ White, PD; Goldsmith, KA; Johnson, AL; Walwyn, R; Baber, HL; Chalder, T; Sharpe, M (May 17, 2011). "(correspondence) The PACE trial in chronic fatigue syndrome – Authors' reply". The Lancet. 377 (9780): 1834–1835. doi:10.1016/S0140-6736(11)60651-X.
  11. ↑ Chalder, T; Goldsmith, KA; White, PD; Sharpe, M; Pickles, AR (April 2015). "(response) Author's reply - Methods and outcome reporting in the PACE trial". The Lancet Psychiatry. 2 (4): e10–e11. doi:10.1016/S2215-0366(15)00114-5.
  12. ↑ Sharpe, M; Goldsmith, KA; Johnson, AL; Chalder, T; Walker, J; White, PD (February 2016). "(correspondence) Authors' reply - Patient reaction to the PACE trial". The Lancet Psychiatry. 3 (2): e8–e9. doi:10.1016/S2215-0366(16)00018-3.
  13. ↑ White, PD; Chalder, T; Sharpe, M; Angus, BJ; Baber, HL; Bavinton, J; Burgess, M; Clark, LV; Cox, DL; DeCesare, JC; Goldsmith, KA; Johnson, AL; McCrone, P; Murphy, G; Murphy, M; O'Dowd, H; Potts, L; Walwyn, R; Wilks, D (January 2017). "Response to the editorial by Dr Geraghty". Journal of Health Psychology. 22 (9): 1113–1117. doi:10.1177/1359105316688953.
  14. ↑ Sharpe, Michael; Goldsmith, Kim; Chalder, Trudie (March 12, 2019). "The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et al". BMC Psychology. 7 (1): 15. doi:10.1186/s40359-019-0288-x. ISSN 2050-7283.

PACE trial A controversial study which claimed that CBT and GET were effective in treating "CFS/ME", despite the fact that its own data did not support this conclusion. Its results and methodology were widely disputed by patients, scientists, and the peer-reviewed scientific literature.

somatic symptom disorder A psychiatric term to describe an alleged condition whereby a person's thoughts somehow cause physical symptoms. The actual existence of such a condition is highly controversial, due to a lack of scientific evidence. It is related to other psychiatric terms, such as "psychosomatic", "neurasthenia", and "hysteria". Older terms include "somatization", "somatoform disorder", and "conversion disorder". Such terms refer to a scientifically-unsupported theory that claims that a wide range of physical symptoms can be created by the human mind, a theory which has been criticized as "mind over matter" parapsychology, a pseudoscience.

Retrieved from "https://me-pedia.org/w/index.php?title=Kimberley_Goldsmith&oldid=235551"